Dian Diagnostics overhauls governance, abolishes supervisory board

Dian Diagnostics Group held its Fifth Board of Directors' Seventeenth Meeting on December 12, 2025, approving the abolishment of its supervisory board. The supervisory board’s functions will now be exercised by the board’s audit committee, leading to the repeal of related corporate governance policies, including the "Rules of Procedure for the Supervisory Board." This decision necessitates extensive amendments to the company’s articles of association and the repeal or revision of 25 existing and 4 new corporate governance policies.

The amendments to the articles of association primarily involve removing supervisory board-related provisions, adjusting shareholder meeting terminology and procedures, revising board structure to include employee directors, and detailing policies for controlling shareholders, independent directors, and special committees. These changes will be effective upon shareholder approval at the First Extraordinary General Meeting on December 31, 2025. The company will also repeal the "Financial Derivatives Trading Management Policy" to align with the new framework.